Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Discounted “Stopgap” PDUFA Renewal Might Prompt Faster FDARA Action

Executive Summary

A proposal circulated by House Democrats to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Senate Health, Education, Labor and Pensions Committee Ranking Republican Michael Enzi, Wyo., has declared

You may also be interested in...



Generic Biologics Bill May Not Ride FDARA But Legislators Will Keep Pushing

House legislators assure the generics industry that they remain committed to generic biologics legislation, though the FDA reform bill reauthorizing the drug user fee program will move ahead without it

Benzodiazepine Coverage Among Medicare Provisions In Child Health Bill

Makers of benzodiazepines could see wider use of their products by Medicare Part D enrollees, under a provision of the child health/Medicare legislative package that cleared the House Ways and Means Committee July 27

Preemption Remains Conference Issue In FDA Bill As Both Sides Declare Victory

The impact of FDA reform legislation on product liability lawsuits could depend in large part on how the House and Senate resolve subtle differences in phrasing between the two chambers' bills

Related Content

UsernamePublicRestriction

Register

PS048788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel